Weiguang Biological Products Gets Nod for Human Prothrombin Complex

Shenzhen Weiguang Biological Products (SHE:002880) received a drug registration certificate from China's National Medical Products Administration for its human prothrombin complex, according to a Frid

MT NewswiresJun 3 04:28 ET

Weiguang Biotech (002880.SZ): Received the “Drug Registration Certificate” for human prothrombin complex

Gelonghui, May 31 | Weiguang Biotech (002880.SZ) announced that it has recently received the approval and issuance of the “Drug Registration Certificate” for the human prothrombin complex from the State Drug Administration. Clinically, it is mainly used to treat congenital and acquired coagulation factor II, VII, IX, and X deficiencies (alone or in combination).

Gelonghui FinanceMay 31 04:13 ET

Weiguang Biology (002880.SZ): The main business is blood products. It is a bioactive preparation prepared from healthy human plasma using biological processes or separation and purification technology

Gelonghui, May 24 | Weiguang Biology (002880.SZ) said on the investor interactive platform that the company's main business is blood products, which are bioactive preparations prepared using biological processes or separation and purification techniques using healthy human plasma as raw materials. Weiguang Life Science Park focuses on synthetic biology, brain science, etc., to build a core technology platform for genes, macromolecules, and cells, and is committed to building a biomedical specialty park characterized by innovation incubation and transformation of results.

Gelonghui FinanceMay 24 04:40 ET

Weiguang Biotech (002880.SZ): Net profit of 468.319 million yuan in the first quarter increased 2.40% year-on-year

Gelonghui, April 25 | Weiguang Biotech (002880.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 226 million yuan, up 8.53% year on year; net profit attributable to shareholders of listed companies was 468.319 million yuan, up 2.40% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 455.227 million yuan, up 1.23% year on year; basic earnings per share were 0.2065 yuan.

Gelonghui FinanceApr 25 08:39 ET

Earnings Growth of 0.8% Over 3 Years Hasn't Been Enough to Translate Into Positive Returns for Shenzhen Weiguang Biological Products (SZSE:002880) Shareholders

You can invest in an index fund if you want to make sure your returns approximately match the overall market. In contrast individual stocks will provide a wide range of possible returns, and may fall

Simply Wall StMar 27 18:31 ET

Some Shareholders Feeling Restless Over Shenzhen Weiguang Biological Products Co., Ltd.'s (SZSE:002880) P/E Ratio

There wouldn't be many who think Shenzhen Weiguang Biological Products Co., Ltd.'s (SZSE:002880) price-to-earnings (or "P/E") ratio of 30.7x is worth a mention when the median P/E in China is similar

Simply Wall StFeb 1 02:15 ET